Merck KGaA steps up push into biosimilars - (Financial Times via NewsPoints Desk)

  • Merck KGaA CEO Karl-Ludwig Kley said that he expected biosimilars to become an important new market as governments seek to lower healthcare costs, the Financial Times reported Sunday.
  • Kley noted that Merck had "all the capabilities to compete in biosimilars" and expected significant growth in the market by "the second half of this decade."
  • In November last year, the company agreed to work with BioNovis of Brazil on six biosimilars for cancer and arthritis following a similar agreement with Dr. Reddy’s.
  • The executive said that he was confident biosimilars would command a higher margin than traditional generics, adding that "we do not think the market will be as crowded as in generics because it is harder and more costly to achieve the required quality."
  • Kley commented that drugmaker's priority would remain developing its own innovative medicines.

To read more NewsPoints articles, click here.

Reference Articles